Imara M&A

Expected Near-term Clinical Milestones for Parallel Lead Product Candidates 2022 2H22 ● ● ELVN-001 Phla initiation (completed) ELVN-002 IND filing ● 2023 ELVN-001 ELVN-001 Potential Pivotal Studies Late line single arm T3151 single arm ponatinib or asciminib intolerant / ineligible Early line H2H vs. Physician's Choice 1H23 ELVN-002 Ph1a initiation CRC = Colorectal cancer. IND = Investigational new drug. NSCLC = non-small cell lung cancer. MBC = metastatic breast cancer. 2H23 ELVN-001 Ph1 early clinical data 2024 1H24 ELVN-002 Phla data ELVN-002 ELVN-002 Potential Pivotal Studies • 2L+ NSCLC HER2 mutant monotherapy ● HER2 amplified MBC monotherapy & combinations HER2 mutant basket, HER2-amp CRC, etc. 17

View entire presentation